Hansa Biopharma announces participation in Fall investor conferences and provides updated financial calendar

Hansa Biopharma to participate in several leading global healthcare conferences in September 

Lund, Sweden August 31, 2021 Hansa Biopharma AB “Hansa”, (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced that the Company’s management team will present at the following upcoming investor conferences during September 2021:

• Erik Penser Access Minibolags dag, Malmö Tuesday August 31, 2021 at 17:15 (CET)
• Pareto Securities Health Care Conference on Thursday September 2 2021, at 13:10 (CET)
• Redburn Gene Therapy Virtual Summit Tuesday September 7, 2021 at 17:35 (CET)/16:35 (BST)
• H.C. Wainwright Global Investment Conference Monday September 13, 2021 at 13:00 (CET)/ 7:00am (EST)
• Morgan Stanley Global Healthcare Conference Tuesday September 14, 2021 (1x1 meetings only)
• Bank of America Merrill Lynch Healthcare Conference Thursday September 16, 2021 (1x1 meetings only)
• Danske Bank Life Science Seminar “Platform companies” Friday September 17, 2021 at 13:00 (CET)

A link to the applicable presentations and webcasts will be available under the “Events & Presentations” section on the Company's website at www.hansabiopharma.com.

Calendar
Aug 31, 2021        Erik Penser Access, Malmö
Sep 2, 2021          Pareto Healthcare Conference, Stockholm (virtual) 
Sep 7, 2021          Redburn Gene Therapy Virtual Summit
Sep 10+13, 2021  HC Wainwright Annual Global Investment Conference (virtual)
Sep 14, 2021        Morgan Stanley Global Healthcare Conference (virtual)
Sep 16, 2021        BAML Global Healthcare Conference (virtual)
Sep 17, 2021        Danske Bank Life Science event "Platform companies" (virtual)
Sep 30, 2021        Erik Penser Temadag Särläkemedel, Stockholm
Oct 21, 2021         Interim report for Jan-Sep 2021
Oct 22+26, 2021   Kempen NDRS EU/US (virtual)
Nov 10, 2021        Ökonomisk Ugebrev Life Science Conference, Copenhagen
Nov 16-18, 2021   Jefferies London Healthcare Conference (virtual)
Nov 25, 2021        Erik Penser Banks Bolagsdag, Stockholm/virtual
Dec 1-2, 2021       Geneva MidCap Event (virtual)
Jan 9-13, 2022     JP Morgan week, San Francisco
Feb 3, 2022          Year-End report for Jan - Dec 2021
April 7, 2022         Annual Report 2021
April 21, 2022       Interim report for Jan - Mar 2022

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.